Loading ......
Influenza virus is called influenza virus for short. The typical clinical symptoms of these epidemic diseases are acute high fever, body pain, significant fatigue and respiratory symptoms. Influenza virus is mainly transmitted through droplets in the air, contact between susceptible and infected persons or contact with contaminated objects. Generally, autumn and winter are its peak seasons. Human influenza is mainly caused by influenza A virus and influenza B virus. Enzyme linked immunosorbent assay (ELISA) kits have become powerful and reliable tools for detecting influenza viruses and their components, such as hemagglutinin (HA), nucleoprotein (NP), and NS1A binding protein (IVNS1ABP). These test kits have a series of advantages, including high sensitivity, specificity, and ease of use, making them indispensable in research and clinical environments.
Influenza viruses have a segmented genome and a helical capsid. It is single-stranded negative-sense RNA viruses. According to the antigenicity of nucleoprotein (NP) of influenza virus, human influenza viruses can be divided into three categories: The respective roles of these proteins include facilitating viral entry into host cells and enabling viral release from the same cells. Influenza B viruses are classified into two lineages: The Influenza B virus consists of two lineages B/Yamagata and B/Victoria yet Influenza C appears less frequently and produces milder symptoms. The immune system targets the HA protein as its main focus and this protein drives both antigenic drift and shift of the virus.
Figure 1. Structure of Influenza Virus. (Panghal, Archna, et al., 2020)

The virus that has entered is very contagious and spreads quickly. The speed and extent of its transmission are related to population density. If the virus that has entered the body is not removed by the cough reflex, or if the virus is not neutralized by the body's specific IgA antibodies and inactivated by nonspecific inhibitors in the mucosal secretions, it can only infect a small number of respiratory epithelial cells. This causes the cells to produce vacuoles and degenerate.

The NA of the virus can reduce the viscosity of the respiratory mucus layer, not only to expose the cell surface receptors, which is conducive to the adsorption of the virus, but also to promote the spread of the virus-containing liquid to the lower respiratory tract. Many respiratory cells are damaged in a short period of time. Influenza viruses usually only cause surface infections, not viremia.
Influenza virus infects respiratory epithelial cells, causing clustered or diffuse shedding of respiratory ciliated epithelial cells, congestion of submucosal cells in the lamina propria, edema with monocyte infiltration, etc. Influenza virus can also infect alveolar epithelial cells, macrophages, etc., causing extensive damage to the alveolar epithelium. The alveolar cavity is filled with inflammatory exudate, pulmonary interstitial edema, and a large number of inflammatory cell infiltration, resulting in pneumonia symptoms. Severe cases may be accompanied by diffuse alveolar injury, manifested as damage and necrosis of alveolar epithelial cells and pulmonary capillary endothelial cells, infiltration of protein rich exudate and inflammatory cells in the lung interstitium and alveolar cavity, congestion and bleeding of pulmonary microvessels, formation of microthrombi, formation of transparent membranes, focal or extensive alveolar collapse, disruption of the qi and blood barrier, leading to ARDS.
Influenza diagnosis depends on both medical examination and laboratory examinations. During the clinical assessment doctors evaluate patient symptoms together with information about their recent flu exposure and influenza outbreak status in the community. Viral infection can also induce the expression of interferon and cellular immune regulation, causing some autoimmune reactions, including high fever, headache, gastrocnemius and systemic muscle pain, etc. The toxin-like products of viral metabolism and the products released by cell necrosis can also cause and aggravate the above reactions. It is not difficult to diagnose influenza in combination with clinical symptoms during the epidemic period, but laboratory tests must be performed for diagnosis or epidemic monitoring, mainly including virus isolation and culture, serological diagnosis and rapid diagnosis methods.
Research indicates that immunization with an HA construct without the globular head domain triggers a wider immune response while protecting against various influenza subtypes. Protection from lethal influenza virus challenges resulted when mice received vaccinations featuring a headless HA construct according to animal model research.The development of vaccines targeting the M2 protein represents another promising strategy since this protein plays a role in viral replication processes. Studies demonstrate that focusing on the M2 protein enables the creation of vaccines with broad protective capabilities. Research demonstrates that virus- like particles (VLPs) effectively generate protective immunity for both identical and different strains of the influenza virus. Virus-like particles (VLPs) reproduce the virus structure yet lack replication ability and stimulate potent immune responses without posing any disease risk.

Fast turnaround time
Most test kits can detect results within 2-3 hours, which is faster than virus culture and on par with RIDT. This allows clinicians to make clinical decisions in a timely manner (eg. start antiviral therapy).

Quantitative Results
In contrast to qualitative RIDT, ELISA provides numerical information on antigen/antibody levels. It can be used to assess the viral load (antigen levels) and quantify the immune status (antibody titers).

Cost Effectiveness
ELISA kits are less expensive than RT-PCR, especially for high-throughput detection. It requires minimal equipment (microplate readers) and can be performed by trained technicians.
The influenza virus ELISA kit is used for the detection and typing of influenza viruses. It can be used in clinical diagnosis, veterinary medicine, and scientific research. The sensitivity, specificity, and convenience of the test kit have made it an indispensable experimental tool for researchers and clinical doctors. The rapid detection and quantification of viral antigens by ELISA will play a vital role in the monitoring and dynamics of influenza virus transmission, vaccine evaluation, and the development of new diagnostic and treatment plans.
Reference
| Cat. No. | Product Name | Size | Species Reactivity | Application | Detection Method | |
| DEIA-CL036 | Influenza A Virus Nucleoprotein Antigen ELISA Kit | 96T | IAV | Quantitation | sELISA | Inquiry |
| DEIA353 | Influenza A IgG ELISA Kit | 96T | Human | Quantitative and Qualitative | ELISA | Inquiry |
| DEIA358 | Influenza B IgM ELISA Kit | 96T | Human | Quantitative and Qualitative | ELISA | Inquiry |
| DEIA1916 | Influenza B Virus IgM ELISA Kit | 96T | Human | Quantitative | Competitive ELISA | Inquiry |
| DEIA1917 | Influenza A Virus IgG ELISA Kit | 96T | Human | Qualitative | Indirect ELISA | Inquiry |
| DEIA1918 | Influenza B Virus IgA ELISA Kit | 96T | Human | Qualitative | Competitive ELISA | Inquiry |
| DEIA1919 | Influenza A Virus IgM ELISA Kit | 96T | Human | Qualitative | Competitive ELISA | Inquiry |
| DEIA1920 | Influenza B Virus IgG ELISA Kit | 96T | Human | Qualitative | Competitive ELISA | Inquiry |
| DEIA1921 | Influenza A Virus IgA ELISA Kit | 96T | Human | Qualitative | Competitive ELISA | Inquiry |
| Cat. No. | Product Name | Host | Isotype | Application | |
| DPAB-L21083 | Anti-IAV H1N1 Neuraminidase Polyclonal antibody | Rabbit | IgG | I-ELISA | Inquiry |
| DPAB-L21217 | Anti-IAV H1N1 Neuraminidase Polyclonal antibody | Rabbit | IgG | I-ELISA | Inquiry |
| CABT-B8414 | Anti-Influenza A H9N2 (A/Hong Kong/1073/99) Neuraminidase polyclonal antibody | Rabbit | IgG | ELISA | Inquiry |
| CABT-BL1383 | Anti-EPN1 (aa 431-480) polyclonal antibody | Rabbit | IgG | WB, ELISA | Inquiry |
| CABT-BL8953 | Anti-Parainfluenza Virus Type 3 p69 polyclonal antibody | Goat | / | IFA | Inquiry |
| DPAB-CS24038A | Human Anti-PIV IgA Control Serum | Human | IgA | ELISA | Inquiry |
| CABT-CS679 | Rabbit Anti-IAV H5N8 HA Polyclonal Antibody | Rabbit | IgG | WB, ELISA | Inquiry |
| Cat. No. | Product Name | Size | Target | Species | |
| DAG-P2864 | PIV type 1 Nucleocapsid (aa 0-0) | / | / | PIV | Inquiry |
| DAG-P2865 | PIV type 3 Nucleocapsid (aa 0-0) | / | / | PIV | Inquiry |
Loading ......